Bicara Therapeutics Inc. Common Stock
Bicara Therapeutics Inc. Common Stock (BCAX) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
bcax · stock forecast · 7 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 7 Wall Street analysts in the past 3 months
Buy
7 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$42.00
Consensus
$28.60
+42.8% upside
Low
$18.00
Median: $28 · Last Close: $20.03
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$28.60
42.8% upside
High Target
$42
109.7%
Low Target
$18
-10.1%
Current Price
$20.03
as of today
Based on analyst price targets, the BCAX stock price prediction for the next 12 months ranges from $18 to $42. The consensus BCAX price forecast of $28.60 implies 42.8% upside from the current price of $20.03.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $19.45 | ↓ 2.90% |
1-day model range: $19.35–$19.55. Peak: $19.55 (-2.90%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $44 | +120.0% |
| 2028 | $73 | +265.2% |
| 2029 | $100 | +397.8% |
| 2030 | $120 | +497.1% |
| 2031 | — | +562.7% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · BCAX · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-12 | Morgan Stanley | Maintains | Overweight→Overweight |
| 2026-05-12 | Goldman Sachs | Maintains | Neutral→Neutral |
| 2026-03-31 | Wedbush | Maintains | Outperform→Outperform |
| 2026-03-31 | Citizens | Maintains | Market Outperform→Market Outperform |
| 2026-03-31 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-03-31 | Goldman Sachs | Maintains | Neutral→Neutral |
| 2026-03-31 | Wells Fargo | Maintains | Equal Weight→Equal Weight |
| 2026-01-13 | Wedbush | Maintains | Outperform→Outperform |
| 2025-11-11 | Wells Fargo | Maintains | Equal Weight→Equal Weight |
| 2025-08-22 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Bicara Therapeutics Inc. Common Stock (BCAX) stock. Of the recent 16 rating actions, 1 were upgrades and 0 were downgrades. 7 analysts currently cover BCAX.
Analyst Recommendation Trends
BCAX analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
↓ 100.0% YoY
Revenue Next Year
$0M
EPS This Year
$-3.49
EPS Next Year
$-3.70
↑ 6.2% YoY
EPS ForecastReported vs Estimated
Analysts forecast BCAX EPS of $-3.49 for the current fiscal year, based on estimates from 11 analysts. The BCAX revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The BCAX stock forecast is supported by two independent data sources: analyst consensus ratings from 7 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus BCAX price target is $28.60 (+42.8% upside), with an analyst consensus of Buy.
The BCAX short-term stock prediction for tomorrow is $19.45 (-2.90%). The BCAX stock price prediction for 2027 estimates an average of $44. The BCAX stock prediction for 2030 projects a range of $113–$127.
Bicara Therapeutics Inc. Common Stock trades on NASDAQ under the ticker BCAX. The BCAX stock outlook for 2027 is broadly positive, supported by a Buy consensus among 71% of covering analysts.
Frequently asked questions
BCAX forecast · 8 questionsAccording to 7 Wall Street analysts, the average 12-month BCAX price target is $28.60, with a high forecast of $42.00 and a low of $18.00. The median price target is shown in the chart above when available. This implies +42.8% potential upside from the current price of $20.03.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.